A phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant prostate cancer (mCRPC).

Nonna Shakhnazaryan, Nathan Curry, Medini Rastogi, Daniel Avins, Shrina Pandey, Ivan de Kouchkovsky, Daniel Kwon, Arpita Desai, Kelly N. Fitzgerald, Rohit Bose, Jonathan Chou, Terence W. Friedlander, Vadim S Koshkin, Lawrence Fong, Maya Aslam, Khadija Siddiqua, Eric J. Small, Bin Liu, Robert R. Flavell, Rahul Raj Aggarwal. A phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2024 Jun 1; 42(16_suppl):5066-5066.